39 completed, 5 unknown, 3 not yet recruiting, 2 withdrawn. 53 Phase 2, 9 Phase 1, 5 Phase 3.
Follow Tinnitus: new trials by email Literature Review of Tinnitus trials Research Report on Tinnitus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Testing Safety and Efficacy of Transtympanic Paliroden for the Treatment of Cochlear Synaptopathy in Participants With Chronic, Constant Tinnitus paliroden (CIL001), Placebo - Tinnitus, Bilateral, Cochlear Synaptopathy | Phase 1 / Phase 2 | Not yet recruiting | Cilcare SAS | 60 | 2027-01-01 | 2026-09-17 |
| Acute Nicotine Gum and Auditory Brain Responses in Adults With Chronic Tinnitus Nicotine polacrilex gum 4 mg, Placebo gum - Tinnitus, Chronic Subjective Tinnitus | Phase 1 / Phase 2 | Not yet recruiting | San Diego State University | 20 | 2026-11-01 | 2026-11-06 |
| A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B) TRTL-913, Placebo - Tinnitus | Phase 2 | Recruiting | Tortugas Neuroscience, Inc. | 100 | 2026-10-14 | 2026-11-04 |
| SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose - Lung Cancer, Head and Neck Cancer | Phase 2 | Withdrawn | Sound Pharmaceuticals, Incorporated | 2026-06-01 | 2026-06-03 | |
| DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine - Tinnitus | Phase 2 | Enrolling by invitation | Leading Edge Clinic | 20 | 2026-05-15 | 2026-05-13 |
| Acute Nicotine Gum and Tinnitus Loudness in Non-Smoking Adults Nicotine polacrilex gum 4 mg, Placebo gum - Tinnitus, Chronic Subjective Tinnitus | Phase 1 / Phase 2 | Completed | San Diego State University | 29 | 2026-03-25 | 2026-10-16 |
| Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease Isosorbide oral solution, Placebo - Meniere´s Disease | Phase 2 / Phase 3 | Not yet recruiting | Lunan Better Pharmaceutical Co., LTD. | 234 | 2024-12-30 | 2025-01-09 |
| Blinding and Adverse Effects of Ultrasonic Vagus Nerve Stimulation (U-VNS) Ultrasound Vagus Nerve Stimulation (U-VNS), Sham U-VNS - U-VNS, Sham U-VNS | Phase 1 / Phase 2 | Completed | University of Nottingham | 20 | 2024-12-10 | 2025-07-29 |
| An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus Brexanolone - Tinnitus | Phase 2 | Completed | Supernus Pharmaceuticals, Inc. | 10 | 2023-05-10 | 2025-09-15 |
| The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial incobotulinum toxin A, Placebo-Saline - Tinnitus | Phase 2 | Completed | University of Minnesota | 41 | 2023-01-01 | 2026-10-27 |
| Effect of Combined Antioxidant Therapy on Oxidative Stress Markers and Inflammatory Cytokines in Patients With Tinnitus Drusen Mega®, Sertraline, Placebo - Tinnitus, Subjective, Tinnitus, Bilateral | Phase 2 | Unknown | University of Guadalajara | 58 | 2022-12-01 | 2023-04-07 |
| TNF-α Treatment of Blast-Induced Tinnitus Etanercept, Saline - Tinnitus, Noise Induced | Phase 2 | Active not recruiting | Wayne State University | 88 | 2022-07-01 | 2026-10-20 |
| OTO-313 in Subjects With Unilateral Subjective Tinnitus OTO-313, Placebo - Subjective Tinnitus | Phase 2 | Completed | Otonomy, Inc. | 153 | 2021-03-22 | 2023-01-06 |
| Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus Ketamine Hydrochloride in saline - Tinnitus | Phase 2 | Completed | New York State Psychiatric Institute | 42 | 2019-09-01 | 2026-03-25 |
| OTO-313 in Subjects With Subjective Tinnitus OTO-313, Placebo - Tinnitus, Subjective | Phase 1 / Phase 2 | Completed | Otonomy, Inc. | 43 | 2019-04-04 | 2022-12-23 |
| A Study on the Effectiveness of Antioxidant Supplementation in Tinnitus Antioxidants, Placebo - Tinnitus | Phase 2 | Completed | National and Kapodistrian University of Athens | 70 | 2019-01-10 | 2019-11-13 |
| SPI-1005 for the Treatment of Patients With Meniere's Disease 200mg SPI-1005 BID, 400mg SPI-1005 BID, Placebo - Meniere's Disease | Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 149 | 2017-09-28 | 2023-09-18 |
| SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity Placebo, SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2 - Ototoxicity | Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 35 | 2017-07-21 | 2026-07-16 |
| Impact of Neurostimulation on Patterns of Brain Electrical Activity in Patients With Tinnitus Transcranial Direct Current Stimulation, Sham Transcranial Direct Current Stimulation - Tinnitus | Phase 2 | Unknown | Federal University of Paraíba | 54 | 2017-02-01 | 2017-01-30 |
| Study to Evaluate SPI-1005 in Adults With Meniere's Disease SPI-1005 - Meniere's Disease | Phase 1 / Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 40 | 2015-12-01 | 2026-06-29 |
Showing 20 of 53. Sign in to see all of them.
Hearing Loss (10) · Vertigo (5) · Meniere Disease (3) · Headache (2) · Hearing Loss, Noise-Induced (2) · Obesity (2) · Ototoxicity (2) · Papilledema (2) · Pseudotumor Cerebri (2) · Anxiety Disorders (1) · Blindness (1) · Bronchiolitis Obliterans Syndrome (1) · Cystic Fibrosis (1) · Deafness (1)
Ear Diseases (53) · Nervous System Diseases (53) · Neurologic Manifestations (53) · Otorhinolaryngologic Diseases (53) · Pathological Conditions, Signs and Symptoms (53) · Sensation Disorders (53) · Signs and Symptoms (53) · Hearing Disorders (52) · Labyrinth Diseases (5) · Vestibular Diseases (5) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Endolymphatic Hydrops (3) · Pathologic Processes (3) · Behavior (2)
ebselen (4) · Gabapentin (3) · Transcranial Magnetic Stimulation (3) · Nicotine Chewing Gum (2) · PDCD5 protein, rat (2) · Sodium Chloride (2) · Transcranial Direct Current Stimulation (2) · 2-(1-(5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl)-3-piperidyl)acetic acid (1) · AUT00063 (1) · Acetaminophen (1) · Acetazolamide (1) · Acetylcysteine (1) · Antioxidants (1) · Aspirin (1) · Betahistine (1)
Sound Pharmaceuticals, Incorporated (4) · Washington University School of Medicine (4) · Otonomy, Inc. (3) · Islamic Azad University of Mashhad (2) · Nottingham University Hospitals NHS Trust (2) · San Diego State University (2) · US Department of Veterans Affairs (2) · University of Iowa (2) · Auris Medical AG (1) · Auris Medical, Inc. (1) · Autifony Therapeutics Limited (1) · Bayer (1) · Brainsway (1) · Centre Hospitalier Universitaire Vaudois (1) · Cilcare SAS (1)
United States (26) · Germany (8) · United Kingdom (7) · Poland (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · France (1) · Greece (1) · Iran (1) · Israel (1) · Lebanon (1) · Mexico (1)
Jonathan Kil, MD (4) · Jay F Piccirillo, MD (2) · Xianhui Wang (2) · Alexandra Sinclair, MbChb PhD (1) · Carl LeBel, PhD (1) · Carol Bauer, MD (1) · Christian Plewnia, M.D. (1) · Colleen G Le Prell, PhD (1) · David Benninger, MD (1) · David McAlpine, PhD (1) · Deborah A Hall, PhD (1) · Deborah Hall, Professor (1) · Derek J Hoare, PhD (1)
PMID 17438255, PMID 17960408, PMID 18193350, PMID 18600443, PMID 19045972, PMID 19698089, PMID 21223542, PMID 21422304, PMID 21751942, PMID 21974483, PMID 22122960, PMID 22168528, PMID 22217183, PMID 23598691, PMID 23599075, PMID 23827090, PMID 24756302, PMID 24756514, PMID 24781936, PMID 24975234, PMID 25017670, PMID 25215617, PMID 25356570, PMID 25370510, PMID 25370513, PMID 25470623, PMID 26024112, PMID 26181507, PMID 26335066, PMID 26618282, PMID 26778344, PMID 26934136, PMID 27694262, PMID 28130349, PMID 28183355, PMID 28492874, PMID 28923789, PMID 30939361, PMID 32483557, PMID 33098644, PMID 33637230, PMID 34510123, PMID 35326273, PMID 36240084, PMID 37740611, PMID 41341514
R01DC005972 (1), R01DC006253 (1), R01DC009095 (1), U01DC008423 (1), U10EY017281 (1), U10EY017387 (1)